Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOS and Adalimumab in Crohn's Disease
NCT02539849Completed
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Dec 2014
- Primary completion
- Dec 2017
- Countries
- 1
01
Overview
Open-label, single-arm trial in Crohn's disease, sponsored by Vall d'Hebron Research Institute. Primary endpoint: Counts of Faecalibacterium prausnitzii in faecal samples at 14 weeks. Started Dec 2014; status: completed.
02
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02539849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02539849.